BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
7.56
-0.12 (-1.56%)
Jun 18, 2026, 4:00 PM EDT - Market closed
BridgeBio Oncology Therapeutics Employees
BridgeBio Oncology Therapeutics had 106 employees as of March 31, 2026. The number of employees increased by 14 or 15.22% since the number was last reported on December 31, 2025.
Employees
106
Change
14
Growth
15.22%
Revenue / Employee
n/a
Profits / Employee
-$1,453,726
Market Cap
605.61M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 106 | 14 | 15.22% |
| Dec 31, 2025 | 92 | 30 | 48.39% |
| Dec 31, 2024 | 62 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ginkgo Bioworks Holdings | 485 |
| Rigel Pharmaceuticals | 174 |
| Prime Medicine | 146 |
| Aclaris Therapeutics | 73 |
| CytomX Therapeutics | 69 |
| Candel Therapeutics | 55 |
| Crescent Biopharma | 55 |
| Bright Minds Biosciences | 26 |
BBOT News
- 2 days ago - BridgeBio Oncology Therapeutics Transcript: AGM 2026 - Transcripts
- 5 weeks ago - BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 5 weeks ago - BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - BridgeBio Oncology Therapeutics Earnings release: Q1 2026 - Filings
- 5 weeks ago - BridgeBio Oncology Therapeutics Quarterly report: Q1 2026 - Filings
- 5 weeks ago - BridgeBio Oncology initiated with a Buy at Canaccord - TheFly
- 5 weeks ago - BridgeBio Oncology initiated with a Buy at Canaccord - TheFly
- 7 weeks ago - BridgeBio Oncology Therapeutics Proxy statement: Proxy filing - Filings